Genome-wide CRISPR/Cas9 screens reveal shared and cell-specific mechanisms of resistance to SHP2 inhibition
Journal of Experimental Medicine · 01.05.2023 · 220 (5)
DOI: 10.1084/jem.20221563 ↗Kurz gefasst
Fachartikel in der Zeitschrift Journal of Experimental Medicine, online erschienen am 23.02.2023. Verfasst von Wei Wei und 5 weiteren Autor:innen. Beteiligte Einrichtung: Laura and Isaac Perlmutter Cancer Center, NYU Grossman School of Medicine, NYU Langone Health , New York, NY, USA. Hauptthemen laut MEDLINE: CRISPR-Cas Systems, Signal Transduction. Die Arbeit wurde bisher 29-mal zitiert (Crossref) und nennt 75 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-SA 4.0). Gefördert von: NHGRI NIH HHS, NCI NIH HHS, National Cancer Institute.
Abstract (Originalsprache)
SHP2 (PTPN11) acts upstream of SOS1/2 to enable RAS activation. Allosteric SHP2 inhibitors (SHP2i) in the clinic prevent SHP2 activation, block proliferation of RTK- or cycling RAS mutant-driven cancers, and overcome “adaptive resistance.” To identify SHP2i resistance mechanisms, we performed genome-wide CRISPR/Cas9 knockout screens on two SHP2i-sensitive cell lines, recovering genes expected to cause resistance (NF1, PTEN, CDKN1B, LZTR1, and RASA2) and novel targets (INPPL1, MAP4K5, epigenetic modifiers). We screened 14 additional lines with a focused CRISPR library targeting common “hits” from the genome-wide screens. LZTR1 deletion conferred resistance in 12/14 lines, followed by MAP4K5 (8/14), SPRED2/STK40 (6/14), and INPPL1 (5/14). INPPL1, MAP4K5, or LZTR1 deletion reactivated ERK signaling. INPPL1-mediated sensitization to SHP2i required its NPXY motif but not lipid phosphatase activity. MAP4K5 acted upstream of MEK through a kinase-dependent target(s); LZTR1 had cell-dependent effects on RIT and RAS stability. INPPL1, MAP4K5, or LZTR1 deletion also conferred SHP2i resistance in vivo. Defining the SHP2i resistance landscape could suggest effective combination approaches.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- Laura and Isaac Perlmutter Cancer Center, NYU Grossman School of Medicine, NYU Langone Health , New York, NY, USA.
- Department of Biology, New York University , New York, NY, USA.
- New York Genome Center , New York, NY, USA.
ORCID-Profile: Wei Wei, Mitchell J Geer, Xinyi Guo, Igor Dolgalev, Neville E Sanjana, Benjamin G Neel
Förderung
- NHGRI NIH HHS
- NCI NIH HHS
- National Cancer Institute
- National Human Genome Research Institute
Zitieren
APA
Wei, W., Geer, M. J., Guo, X., Dolgalev, I., Sanjana, N. E., & Neel, B. G. (2023). Genome-wide CRISPR/Cas9 screens reveal shared and cell-specific mechanisms of resistance to SHP2 inhibition. Journal of Experimental Medicine, 220(5). https://doi.org/10.1084/jem.20221563
Vancouver
Wei W, Geer MJ, Guo X, Dolgalev I, Sanjana NE, Neel BG. Genome-wide CRISPR/Cas9 screens reveal shared and cell-specific mechanisms of resistance to SHP2 inhibition. Journal of Experimental Medicine. 2023;220(5). doi:10.1084/jem.20221563
BibTeX
@article{Wei2023,
author = {Wei, Wei and Geer, Mitchell J and Guo, Xinyi and Dolgalev, Igor and Sanjana, Neville E and Neel, Benjamin G},
title = {Genome-wide CRISPR/Cas9 screens reveal shared and cell-specific mechanisms of resistance to SHP2 inhibition},
journal = {Journal of Experimental Medicine},
year = {2023},
volume = {220},
number = {5},
doi = {10.1084/jem.20221563}
}
EUVIMED